[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eighth Affiliated Hospital, Sun Yat-sen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":209},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,70,99,127,151,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643142","phase-1-safety-and-efficacy-of-allogeneic-bone-marrow-mscs-in-ankylosing-spondylitis-100643142",false,"NCT07632599","Safety and Efficacy of Allogeneic Bone Marrow MSCs in Ankylosing Spondylitis","An Early Exploratory Clinical Study on the Safety and Preliminary Efficacy of Allogeneic Human Bone Marrow Mesenchymal Stem Cells in Patients With Ankylosing Spondylitis","Inclusion Criteria:\n\n* Meet the diagnostic criteria for ankylosing spondylitis (AS)\n* Age 18 to 40 years\n* Must be able to understand and communicate with the investigator, comply with study requirements, and provide signed and dated informed consent before any study assessments are performed\n* Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) total score ≥ 4 (0-10 scale), and total back pain measured by VAS ≥ 40 mm (0-100 mm)\n* CRP or ESR elevated ≥ 1.5 times the upper limit of normal\n* Patients taking methotrexate (≤ 25 mg\u002Fweek) or sulfasalazine (≤ 3 g\u002Fday) are permitted to continue these medications, provided they have been used for at least 3 months and maintained at a stable dose for at least 4 weeks prior to randomization. Patients taking methotrexate must maintain stable folic acid supplementation prior to randomization\n* Patients taking DMARDs other than methotrexate and sulfasalazine must discontinue them at least 4 weeks prior to randomization\n* No prior use of any form of biologics within 6 months\n* Spinal X-ray must rule out complete rigid ankylosis\n\nExclusion Criteria:\n\n* Known allergy to any component of the study drug (primarily bone marrow mesenchymal stem cells; excipients include dimethyl sulfoxide, human albumin, etc.)\n* Current evidence of infection or malignancy as shown by chest X-ray or MRI within 3 months prior to screening\n* Currently using potent opioid analgesics\n* Received any intra-articular injection therapy (e.g., corticosteroids) within 4 weeks prior to randomization\n* Received any intramuscular corticosteroid injection within 2 weeks prior to randomization\n* Received traditional Chinese medicine treatment for AS within 4 weeks prior to randomization\n* Pregnant or breastfeeding women\n* Presence of underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal disease that, in the investigator's opinion, would place the patient at unacceptable risk if treated with immunomodulatory agents\n* Significant health problem or disease including (but not limited to): uncontrolled hypertension (≥ 160\u002F95 mmHg), congestive heart failure, uncontrolled diabetes, or extremely poor functional status rendering the patient unable to care for themselves\n* History of renal impairment, glomerulonephritis, or a single kidney, or serum creatinine level \\> 1.5 mg\u002FdL\n* Active systemic infection within 2 weeks prior to randomization (common cold excluded)\n* Current infection or history of chronic, recurrent infectious disease, or clinical test suggesting tuberculosis (including latent tuberculosis)\n* Known HIV infection, hepatitis B, or hepatitis C at screening or randomization\n* History or evidence of alcohol or drug abuse within 6 months prior to randomization\n* History of lymphoproliferative disease or known malignancy of any organ system within the past 5 years\n* Pulmonary arterial hypertension class III or IV (WHO functional classification) at screening\n* History of deep vein thrombosis at screening, or history of pulmonary embolism within 3 months prior to screening\n* Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in the study (e.g., lack of compliance, difficulty in long-term follow-up)","ALL","18 Years","40 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to learn if allogeneic human bone marrow-derived mesenchymal stem cells (CG-BM1) are safe and show preliminary efficacy in treating patients with ankylosing spondylitis (AS). It will also explore the appropriate dose of CG-BM1.\n\nThe main questions it aims to answer are:\n\nWhat medical problems (adverse events) do participants have when taking CG-BM1? (Safety and tolerability)\n\nDoes CG-BM1 improve disease activity, pain, and function in patients with AS? (Preliminary efficacy)\n\nResearchers will compare CG-BM1 to a placebo (an inactive substance that looks like CG-BM1) in the second phase of the study to see if CG-BM1 works for AS.\n\nThis study has two phases:\n\nPhase 1 (dose-escalation): Open-label, single-arm. Participants will receive one of three escalating doses of CG-BM1 weekly for 4 weeks.\n\nPhase 2 (dose-expansion): Randomized, double-blind, placebo-controlled. Participants will receive either the recommended dose of CG-BM1 or a placebo weekly for 4 weeks, in addition to standard background therapy (celecoxib).\n\nParticipants will:\n\nReceive CG-BM1 or placebo via intravenous infusion once a week for 4 weeks\n\nVisit the clinic for follow-up assessments at Week 1, 4, 8, 12, and 24 after the first infusion\n\nUndergo physical exams, laboratory tests (blood and urine), and complete questionnaires about disease activity, pain, and function (e.g., BASDAI, VAS, ASAS response criteria)",[27],"Ankylosing Spondylitis","NOT_YET_RECRUITING","2026-06-02",{"date":31,"type":32},"2026-06-08","ACTUAL",{"date":34,"type":21},"2026-07-01",{"date":36,"type":21},"2027-06-01",{"name":38,"class":39},"Eighth Affiliated Hospital, Sun Yat-sen University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":40},"100638925","fecal-microbiota-transplantation-fmt-combined-with-calorie-restricted-diet-and-semaglutide-in-patients-with-obesity-and-type-2-diabetes-100638925","NCT07599046","Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes","Effects of Comprehensive Intervention With Fecal Microbiota Transplantation Versus Conventional Treatment on Body Weight and Metabolism in Patients With Obesity Complicated by Type 2 Diabetes Mellitus: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-60 years;\n2. Body mass index (BMI) ≥30 kg\u002Fm² and \\\u003C40 kg\u002Fm²;\n3. Duration of type 2 diabetes mellitus \\\u003C1 year;\n4. Non-smoker or smoking cessation \\>3 months;\n5. Voluntary signed informed consent with commitment to complete the entire study.\n\nExclusion Criteria:\n\n1. Complicated with severe hepatic or renal insufficiency (alanine aminotransferase\u002Faspartate aminotransferase \\[ALT\u002FAST\\] \\>3 times the upper limit of normal, or estimated glomerular filtration rate \\[eGFR\\] \\\u003C60 mL\u002Fmin\u002F1.73 m²);\n2. Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or other organic intestinal diseases; autoimmune diseases, malignancies, or active infections;\n3. Medication and intervention exclusions: Use of α-glucosidase inhibitors, antibiotics, proton pump inhibitors (PPIs), or probiotics\u002Fprebiotics within the past 3 months; bariatric surgery within the past 6 months; long-term use of immunosuppressants or glucocorticoids;\n4. Others: Pregnant or lactating women; currently participating in other clinical trials.","60 Years",{"count":50,"type":21},20,[52],"NA","Investigation of the efficacy of fecal microbiota transplantation added to calorie-restricted diet and semaglutide versus calorie-restricted diet and semaglutide alone for weight loss and metabolic improvement in patients with moderate to severe obesity and type 2 diabetes mellitus.",[55],"Obesity Type 2 Diabetes Mellitus",[57,58,59,60,61],"Type 2 diabetes mellitus","Obesity","Fecal microbiota transplantation","Calorie-restricted diet","Semaglutide","2026-05-13",{"date":64,"type":32},"2026-05-20",{"date":66,"type":21},"2026-04-30",{"date":68,"type":21},"2029-12-30",{"name":38,"class":39},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":40},"100620365","hemi-tibial-plateau-osteotomy-combined-with-arthroscopic-repair-for-medial-meniscus-posterior-root-tears-in-varus-knees-100620365","NCT07356674","Hemi-tibial Plateau Osteotomy Combined With Arthroscopic Repair for Medial Meniscus Posterior Root Tears in Varus Knees","Hemi-tibial Plateau Osteotomy Combined With Arthroscopic Repair for Medial Meniscus Posterior Root Tears in Varus Knees: A Single-center, Randomized, Controlled, Open-label, Non-inferiority Study","Inclusion Criteria:\n\n* Age 35 to 75 years, with no restriction on sex.\n* Clinical features suggestive of a medial meniscus posterior root tear, including at least one of the following symptoms: knee locking, clicking, or medial knee pain; and at least one of the following signs: medial joint line tenderness or a positive McMurray test.\n* Varus knee deformity with a varus angle of less than 10 degrees, with the deformity predominantly originating from the tibia (i.e., medial proximal tibial angle less than 87 degrees).\n* Knee MRI demonstrates a medial meniscus posterior root tear.\n* Knee radiographs show narrowing of the medial joint space, and Kellgren-Lawrence grade less than IV.\n* Failure of conservative treatment (e.g., rest, medication, or physical therapy) for more than 1 month.\n* Willing to accept randomization and able to understand and sign the informed consent form.\n* For participants with bilateral deformity, the more severely deformed side will be selected as the operative (study) side.\n\nExclusion Criteria:\n\n* Chronic knee locking (e.g., the participant cannot bend or fully straighten the knee).\n* Kellgren-Lawrence grade IV knee osteoarthritis.\n* Osteoarthritis or other conditions in other joints (e.g., hip or ankle) that may affect assessment of knee function.\n* Known inflammatory diseases or other conditions that may affect knee function, including but not limited to: autoimmune diseases (e.g., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus); crystal-induced arthritis (gout, pseudogout); secondary knee osteoarthritis due to trauma or other diseases; active knee joint infection or a history of knee joint infection; reactive arthritis; systemic cartilage disorders; systemic connective tissue diseases; metabolic bone disease; fracture (acute or subacute fracture within 6 months prior to the screening visit); osteonecrosis; or abnormal inflammatory markers (C-reactive protein or high-sensitivity C-reactive protein at least 2 times the upper limit of normal, or erythrocyte sedimentation rate at least 3 times the upper limit of normal), if judged by the investigator to be unsuitable for participation.\n* Target-knee instability (including but not limited to post-traumatic or congenital laxity) or inadequate ligament reconstruction, as judged by the investigator.\n* Any prior surgery on the target knee or on other joints of the ipsilateral lower limb.\n* Serious cardiac disease; hepatic impairment (aspartate aminotransferase or alanine aminotransferase at least 3 times the upper limit of normal, or total serum bilirubin at least 1.5 times the upper limit of normal); renal impairment (serum creatinine at least 1.5 times the upper limit of normal); other musculoskeletal disorders; malignancy; coagulation disorders; immunodeficiency; or psychiatric disorders, if judged by the investigator to be unsuitable for participation.\n* Body mass index at least 30 kg\u002Fm².\n* Pregnant or breastfeeding women, or participants (including men and women) unwilling to use contraception during the study period.\n* Participation in another clinical study within 3 months prior to enrollment (excluding registry studies).\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation.","35 Years","75 Years",{"count":50,"type":21},[52],"This is a single-center clinical trial started by the study team. The goal is to compare two surgeries for people who have a varus knee alignment and a tear at the back attachment of the medial meniscus. Researchers want to learn how the newer bone-cut procedure with arthroscopic meniscus repair compares to the standard bone-cut procedure with arthroscopic meniscus repair. Researchers will also track safety and hospital-related costs.\n\nMain questions the study aims to answer:\n\n* At 12 months after surgery, how does the improvement in knee function compare between the newer-surgery group and the standard-surgery group? The study will evaluate preliminary trends in clinical efficacy using the Lysholm knee function score.\n* Do the two groups differ in pain relief, imaging findings, meniscus healing, complications, and hospital stay and preliminary cost-effectiveness? The study plans to enroll about 20 participants at Sun Yat-sen University Eighth Affiliated Hospital (Shenzhen Futian). Participants will be assigned by chance, like drawing lots, in a one-to-one ratio. This is an pilot study with a PROBE (Prospective Randomized Open-label Blinded-Endpoint) design. While participants and surgeons will know which surgery is performed, the research assistant responsible for collecting patient-reported outcomes will be blinded to group allocation to minimize observer bias.\n\nStudy groups:\n\n* Experimental group: hemi-tibial plateau osteotomy plus arthroscopic meniscus repair.\n* Control group: high tibial osteotomy plus arthroscopic meniscus repair.\n\nWho may join:\n\n* Age 35 to 65 years, with no restriction on sex;\n* Diagnosed with a medial meniscus posterior root tear;\n* Presence of varus knee deformity;\n* Imaging findings support the diagnosis (e.g., knee MRI);\n* Failure of conservative treatment: no meaningful improvement after more than 1 month of non-surgical management (e.g., rest, medication, or physical therapy);\n* Varus alignment angle less than 10 degrees;\n* The deformity is predominantly tibial in origin;\n* Knee radiographs do not show the most severe osteoarthritis (Kellgren-Lawrence grade other than IV).\n\nWho cannot join:\n\n* A knee that is chronically \"locked,\" meaning it cannot bend or straighten normally.\n* The most severe level of knee arthritis on knee X-ray.\n* Severe arthritis in the hip or ankle that could affect knee function testing.\n* Inflammatory or infectious conditions that can affect the knee, or abnormal inflammation blood tests that make participation unsafe.\n* Knee instability or poorly functioning prior ligament reconstruction, based on the study doctor's judgment.\n* Any prior surgery on the target knee, or on other joints of the same-side lower limb.\n* Serious heart, liver, or kidney disease, cancer, bleeding disorders, immune deficiency, or severe mental health conditions that make participation unsafe.\n* Body mass index of 30 or higher.\n* Pregnancy or breastfeeding, or not willing to use birth control during the study.\n* Participation in another clinical study within the past 3 months (except registry studies).\n* Any other reason the study doctor believes makes participation unsafe or not appropriate.\n\nWhat participants will do:\n\n* Complete screening and baseline assessments within about 30 days before surgery and sign informed consent.\n* Receive the assigned surgery during the hospital stay.\n* Return for follow-up visits at 3 months, 6 months, and 12 months after surgery.\n* Complete knee function and symptom questionnaires and rate pain at each follow-up visit.\n* Have standing knee X-rays and full-length leg X-rays at 3, 6, and 12 months.\n* Have an MRI of the operated knee at 3, 6, and 12 months to assess meniscus healing and meniscus extrusion.\n\nOutcomes:\n\n* Primary outcome: change from baseline to 12 months in the Lysholm knee function score.\n* Secondary outcomes: changes in the Lysholm score at 3 and 6 months; changes in the WOMAC knee arthritis symptom score at 3, 6, and 12 months; changes in pain rating on a standard pain scale at 3, 6, and 12 months; imaging measures and bone healing on X-rays; meniscus healing and extrusion on MRI; surgery time and blood loss; complications during and after surgery; length of hospital stay and hospital costs; and quality of life utility value from a standard health questionnaire.",[83,84],"Knee Osteoarthristis","Meniscus Injury",[86,87,88,89],"Hemi-tibial plateau osteotomy","High tibial osteotomy","Medial meniscus posterior root tears","Varus knees","RECRUITING","2026-04-28",{"date":93,"type":32},"2026-05-04",{"date":95,"type":32},"2026-03-01",{"date":97,"type":21},"2028-12-31",{"name":38,"class":39},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":109,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":4},"100621995","clinical-characteristics-and-immune-escape-mechanism-of-nontuberculous-mycobacterial-lung-disease-in-south-china-100621995","NCT07377864","Clinical Characteristics and Immune Escape Mechanism of Nontuberculous Mycobacterial Lung Disease in South China","NTM-LD","Inclusion Criteria:1. (Both Cohorts):\n\n* Patients diagnosed with nontuberculous mycobacterial according to standard guidelines.\n* Aged 18 years or older.\n* Available medical records covering the period from 2015 to 2025 (for the retrospective cohort).\n\n  2\\. (Prospective Sub-cohort Additional):\n* Willing and able to provide written informed consent for biospecimen collection.\n* Clinically stable and suitable for undergoing research bronchoalveolar lavage (BAL) procedure, as judged by the investigator.\n\nExclusion Criteria: 1. (Both Cohorts):\n\n* Active tuberculosis or other dominant pulmonary infections.\n* Incomplete medical records that preclude adequate data extraction (for retrospective analysis).\n\n  2\\. (Prospective Sub-cohort Additional):\n* Contraindications to bronchoscopy or BAL procedure.\n* Pregnancy or lactation.\n* Any condition that, in the opinion of the investigator, would compromise patient safety or data integrity.","80 Years",{"count":108,"type":21},1500,"12 Months","OBSERVATIONAL","Nontuberculous Mycobacterial lung disease (NTM-LD) is a significant infectious challenge. The precise causes remain unclear, diagnosis can be complex, treatment outcomes are often unsatisfactory, and the disease can severely affect a patient's quality of life. Environmental factors, such as the warm and humid climate in South China, may contribute to unique characteristics of NTM in this region, but systematic research is currently lacking.\n\nThis study aims to improve the understanding of NTM-LD in South China. It consists of two complementary parts:\n\n1. The first part is a retrospective review of medical records from approximately 1,500 NTM patients across multiple hospitals in South China. This analysis seeks to identify common patterns in symptoms, diagnostic findings, and treatment responses within this population.\n2. The second part is a prospective study involving about 106 current NTM-LD patients. Blood and lung fluid samples will be collected to analyze, using advanced laboratory techniques, how the patient's immune system responds to the infection. This investigation aims to uncover clues about why some cases are difficult to treat.\n\nThe overall goal of this research is to generate evidence that can aid healthcare providers in South China in diagnosing and managing NTM-LD more effectively. Please note that this is an observational study; no new drugs or experimental treatments are being tested.",[113,114],"Nontuberculous Mycobacterial Lung Disease","Mycobacterium Avium Complex (MAC)",[116,117,118,119],"Nontuberculous Mycobacterial","South China","Immune Escape","Outcome","2026-01-28",{"date":122,"type":32},"2026-01-30",{"date":124,"type":21},"2026-01-01",{"date":97,"type":21},{"name":38,"class":39},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100620039","gut-microbiota-and-serum-metabolites-as-predictors-of-glycemic-variability-and-outcomes-in-diabetic-kidney-disease-100620039","NCT07352436","Gut Microbiota and Serum Metabolites as Predictors of Glycemic Variability and Outcomes in Diabetic Kidney Disease","Prospective Cohort Study on the Impact of Gut Microbiota and Serum Metabolites on Glycemic Variability and Clinical Outcomes in Patients With Diabetic Kidney Disease","Inclusion Criteria:\n\n1. Age 18-65 years\n2. Diagnosis of Diabetic Kidney Disease (DKD)\n3. Type 2 Diabetes Mellitus\n4. Stable Antidiabetic Regimen:The antidiabetic regimen must have been stable for at least 3 months prior to study enrollment.\n5. Willingness to Provide Informed Consent:\n\nParticipants must voluntarily sign an informed consent form to participate in the study. -\n\nExclusion Criteria:\n\n1. Acute Diabetic Complications:\n\n   Participants with acute diabetic complications, such as diabetic ketoacidosis (DKA), or with primary kidney diseases like primary glomerulonephritis, nephrotic syndrome, or lupus nephritis.\n2. Infection or Stress Conditions:\n\n   Participants in a state of infection, trauma, or other stress conditions.\n3. Pregnancy or Lactation:\n\n   Women who are pregnant, breastfeeding, or planning to become pregnant in the next month.\n4. Severe Dermatologic Conditions:\n\n   Participants with severe dermatologic conditions, such as extensive eczema, widespread scars, tattoos, herpetic dermatitis, severe edema, or psoriasis.\n5. Skin Issues with Sensor Application:\n\n   Participants with severe skin issues at the site of sensor application, such as burns, injuries, sunburns, ulcers, or scars from prior surgery.\n6. Coagulation or Blood Disorders:\n\n   Participants with abnormal coagulation, anemia, or abnormal hematocrit.\n7. Chronic Gastrointestinal Diseases or Surgery History:\n\n   Participants with chronic gastrointestinal diseases or a history of gastrointestinal or biliary surgery.\n8. Recent Probiotic or Antibiotic Use:\n\nParticipants who have used probiotics or prebiotics, or received antibiotic treatment for more than 3 days in the past 3 months, or have consumed yogurt or yogurt-containing foods\u002Fbeverages in the past week.","65 Years",{"count":136,"type":21},270,"Diabetic kidney disease (DKD) is one of the main complications of diabetes and a leading cause of end-stage kidney disease. Blood glucose variability is closely associated with disease progression in individuals with DKD. Recent evidence suggests that gut bacteria and their circulating metabolites may play important roles in regulating blood glucose variability and clinical outcomes. However, it remains unclear whether gut bacteria and blood metabolites influence DKD progression through effects on blood glucose variability.\n\nThis study aims to (1) characterize gut bacteria and blood metabolites in individuals with DKD at different stages and levels of disease severity, and evaluate their value in predicting adverse outcomes; (2) assess the relationships among gut bacteria, blood metabolites, and blood glucose variability; and (3) determine whether gut bacteria and blood metabolites affect clinical outcomes by modulating blood glucose variability.\n\nA total of 270 individuals with DKD will be enrolled in a prospective observational cohort. The investigators will conduct continuous glucose monitoring and collect stool and blood samples for advanced analyses of gut microbiota and blood metabolites. The objective is to clarify how gut bacteria and circulating metabolites relate to blood glucose variability and disease prognosis, and to develop tools to identify high-risk individuals at an early stage. Ultimately, the findings may provide new insights and strategies to improve clinical care and quality of life for individuals with DKD.",[139],"Diabetic Kidney Disease",[139,141,142],"Glycemic Variability","Gut Microbiota","2026-01-12",{"date":145,"type":32},"2026-01-20",{"date":147,"type":21},"2026-02-01",{"date":149,"type":21},"2029-07-30",{"name":38,"class":39},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100572514","phase-3-optimization-of-keverprazan-amoxicillin-dual-therapy-for-eradicating-helicobacter-pylori-infection-100572514","NCT06734260","Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection","Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection：a Multicenter, Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n1. Aged 18 to 75 years;\n2. Adult subjects who voluntarily signed written informed consent approved by the ethics committee to consent to participate in this study before the start of any study procedure;\n3. Subjects who can understand and comply with the protocol requirements and agree to attend all study visits;\n4. During the screening phase, patients who were Hp positive and required Hp eradication therapy as judged by the investigator, and patients who had failed Hp eradication for the first time;\n5. Participants agreed to use appropriate medical methods of contraception (except medically sterilized status) during the study.\n\nExclusion Criteria:\n\n* 1\\. Participated in other clinical studies within 4 weeks before screening; 2. Pregnant or lactating women; 3. Known allergy to keverprazan, esomeprazole, penicillins or other beta-lactams, macrolide antibiotics, nitrofuran antibiotics, or bismuth (including any relevant adjuvants). If skin sensitivity testing (skin testing) was required, it was performed at visit 1 according to routine medical practice; 4. Participants had a history of drug (including but not limited to opioids) abuse or alcohol abuse (\\> 14 units of alcohol per week, 1 unit of alcohol ≈360mL of approximately 5% beer or 45 ml of approximately 40% spirits or 150 ml of approximately 12% wine) in the year before the screening visit; 5. The subjects had Zolie-Ellison syndrome, gastric acid hypersecretion, or a history of gastric acid hypersecretion; 6. The subject has undergone previous surgery or operation that may affect gastric acid secretion or drug absorption, such as subtotal gastrectomy, total gastrectomy, vagotomy, intestinal resection, etc. Simple surgery for perforation, appendectomy, cholecystectomy, and endoscopic resection of benign tumors are acceptable; 7. \"Warning\" symptoms such as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or hematochezia that might indicate the presence of a malignant GI lesion, unless a malignant lesion was ruled out by endoscopy; 8. A history of malignancy within 5 years before screening (participants were allowed to participate if they had been cured of skin basal cell carcinoma or cervical carcinoma in situ); 9.. Upper gastrointestinal endoscopy showed acute upper gastrointestinal bleeding, active gastric or duodenal ulcer, acute gastric or duodenal mucosal injury; 10. According to the investigator's judgment, the subject has uncontrolled and unstable liver, kidney, cardiovascular, respiratory, gastrointestinal, endocrine, hematological, central nervous system or mental diseases, etc., and participating in the study may affect the safety of the subject or the interpretation of the study results; 11. Subjects who plan to be hospitalized for surgical treatment during the study; 12. H2-receptor antagonist or PPI use within 14 days prior to screening 13C-urea breath test; During the screening period, antibiotics, bismuth and some traditional Chinese medicine with antibacterial effect were taken within 28 days before 13C-urea breath test; 13. Abnormal laboratory test results at screening in any of the following: AST \\> upper limit of normal (ULN); ALT \\> Upper limit of normal (ULN); Total bilirubin \\> ULN; creatinine \\> 1.5 times ULN; 14. The subjects had clinically significant abnormal electrocardiogram (ECG), including severe arrhythmia, multifocal premature ventricular contractions (PVC), second degree or above atrioventricula",true,{"count":160,"type":21},477,[162],"PHASE3","Eradication of HP can significantly improve and reduce HP-related diseases. A 10-14 day quadruple regimen containing bismuth as first-line treatment, achieving an eradication rate of more than 85%. However, some disadvantages of these quadruple regimens, such as severe adverse reactions, high medical costs and low compliance, prevent their application in clinical practice. High-dose proton pump inhibitors (PPI) combined with amoxicillin can be used as the first-line treatment for HP eradication, with good efficacy and compliance and low rate of adverse reactions. However, the acid inhibition effect of PPI mainly depends on the degree of individual metabolism of proton pump,which might influence the eradication effect. Keverprazan, a new competitive potassium acid blocker(P-CAB), is not affected by gene polymorphism, and has the advantage of stronger and longer inhibition effect on gastric acid compared with PPIs. This study aimed to evaluate two different doses of therapy (1 g b.i.d. vs. 1.0 g t.i.d.) and two different durations of therapy (14 vs.10 days) to gain insights of the effectiveness of Keverprazan-amoxicillin dual therapy .",[165],"Helicobacter Pylori Eradication Rate","2025-11-30",{"date":168,"type":32},"2025-12-05",{"date":170,"type":32},"2024-09-10",{"date":172,"type":21},"2026-01-10",{"name":38,"class":39},4,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":40},"100595853","the-effects-of-the-control-strategies-of-wearable-lower-limb-rehabilitation-robots-100595853","NCT07037849","The Effects of the Control Strategies of Wearable Lower Limb Rehabilitation Robots","Effects of Control Strategies in Wearable Lower Limb Rehabilitation Robots","Inclusion Criteria:\n\nStroke patients aged between 18 and 75 years. Patients who are medically stable and able to stand and walk independently for at least 10 meters during rehabilitation.\n\nStroke event occurred at least 3 months ago Patients with impaired lower limb motor function but with some degree of muscle activity in the lower extremities.\n\nPatients without severe cognitive impairment and capable of understanding and following the treatment protocol.\n\nPatients without severe balance or coordination disorders, able to maintain balance and perform gait training with assistive devices.\n\nPatients without lower limb fractures or other serious skeletal issues affecting the lower limbs.\n\nPatients without severe cardiovascular or other serious illnesses and able to tolerate the intensity and duration of rehabilitation therapy.\n\nPatients willing to participate in the study and able to provide written informed consent.\n\nExclusion Criteria:\n\nSevere cognitive impairment that prevents the patient from understanding or complying with the treatment protocol.\n\nSevere balance or coordination disorders that prevent the patient from maintaining balance and participating in gait training, even with assistive devices.\n\nOther serious motor disorders, such as abnormal muscle tone or ataxia, which may interfere with the effectiveness of rehabilitation therapy.\n\nActive cardiovascular disease or other serious systemic illnesses that may affect the patient's safety or treatment outcomes.\n\nLower limb fractures or other serious skeletal issues that may impact the suitability and safety of robot-assisted rehabilitation therapy.\n\nPatients currently receiving other rehabilitation or experimental treatments. Patients with skin ulcers, infections, or other severe skin conditions that may interfere with the use and application of robotic devices.\n\nUnexplained discomfort or pain symptoms that may limit the patient's ability to participate in rehabilitation therapy.\n\nFailure to meet other specific inclusion criteria outlined in the study protocol.",{"count":183,"type":21},10,[52],"Post-stroke patients were required to complete a session of robot-assisted training, which involved nine repetitions of 5-meter overground walking (three trials for each of the three controllers) in a rectangular hospital corridor.",[187,188,189],"Stroke","Gait Training","Gait Disorders",[191,192,193,194,195,196,197,198,199,200],"Robots","Assistive robots","Trajectory","Torque","Force","Robot kinematics","Knee","Limb","Muscles","Hip","2025-06-17",{"date":203,"type":32},"2025-06-26",{"date":205,"type":32},"2024-10-23",{"date":207,"type":21},"2027-04-22",{"name":38,"class":39},""]